Report from the extraordinary general meeting in Orexo AB, 6 August 2013

The extraordinary general meeting resolved on 6 August on amendment to
Performance-based, Long-term Incentive Program 2011/2021, issue of warrants with
the right to subscribe for new shares and approval of disposal of the warrants.

For more information regarding the resolutions at the extraordinary general
meeting reference is made to the complete proposal which is available on the
company’s webpage.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: + 46-703 50 78 88, Email: nikolaj.sorensen@orexo.com

About Orexo
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology. Orexo’s expertise is within the area of reformulation
technologies and especially sublingual formulations. The company has a portfolio
of revenue-generating US and EU approved products currently marketed under
license and a pipeline of several reformulations of approved compounds for areas
of unmet medical need. Orexo also has collaboration projects with several
international pharmaceutical companies. Orexo, with its headquarters in Sweden,
is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo AB please visit www.orexo.com.

Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 16:45 CET on August 6, 2013.